Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

InMed Pharmaceuticals (INM) Operating Expenses: 2021-2025

Historic Operating Expenses for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $2.2 million.

  • InMed Pharmaceuticals' Operating Expenses fell 0.20% to $2.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.6 million, marking a year-over-year increase of 9.25%. This contributed to the annual value of $9.7 million for FY2025, which is 3.83% up from last year.
  • Latest data reveals that InMed Pharmaceuticals reported Operating Expenses of $2.2 million as of Q3 2025, which was down 7.21% from $2.4 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Operating Expenses ranged from a high of $6.8 million in Q2 2022 and a low of $2.0 million during Q4 2023.
  • Its 3-year average for Operating Expenses is $2.3 million, with a median of $2.3 million in 2025.
  • Per our database at Business Quant, InMed Pharmaceuticals' Operating Expenses slumped by 69.64% in 2023 and then skyrocketed by 37.88% in 2024.
  • Quarterly analysis of 5 years shows InMed Pharmaceuticals' Operating Expenses stood at $4.4 million in 2021, then tumbled by 46.99% to $2.3 million in 2022, then declined by 16.03% to $2.0 million in 2023, then surged by 37.88% to $2.7 million in 2024, then dropped by 0.20% to $2.2 million in 2025.
  • Its Operating Expenses stands at $2.2 million for Q3 2025, versus $2.4 million for Q2 2025 and $2.3 million for Q1 2025.